DE18795T1 - Einen monoklonalen antikoerper produzierende hybridzellinie, antikoerper und verfahren zu seiner herstellung, diesen antikoerper enthaltende therapeutische zusammensetzung und deren diagnostische und therapeutische verwendungen. - Google Patents

Einen monoklonalen antikoerper produzierende hybridzellinie, antikoerper und verfahren zu seiner herstellung, diesen antikoerper enthaltende therapeutische zusammensetzung und deren diagnostische und therapeutische verwendungen.

Info

Publication number
DE18795T1
DE18795T1 DE198080301357T DE80301357T DE18795T1 DE 18795 T1 DE18795 T1 DE 18795T1 DE 198080301357 T DE198080301357 T DE 198080301357T DE 80301357 T DE80301357 T DE 80301357T DE 18795 T1 DE18795 T1 DE 18795T1
Authority
DE
Germany
Prior art keywords
cells
antibody
monoclonal antibody
hybridoma
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE198080301357T
Other languages
German (de)
English (en)
Inventor
Gideon Gideon Short Hills New Jersey Goldstein
Patrick Chung-Shu Patrick Chung-Shu Bridgewater New Jersey Kung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21871750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE18795(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Publication of DE18795T1 publication Critical patent/DE18795T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hybrid Cells (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
DE198080301357T 1979-04-26 1980-04-25 Einen monoklonalen antikoerper produzierende hybridzellinie, antikoerper und verfahren zu seiner herstellung, diesen antikoerper enthaltende therapeutische zusammensetzung und deren diagnostische und therapeutische verwendungen. Pending DE18795T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/033,669 US4361549A (en) 1979-04-26 1979-04-26 Complement-fixing monoclonal antibody to human T cells, and methods of preparing same

Publications (1)

Publication Number Publication Date
DE18795T1 true DE18795T1 (de) 1984-07-19

Family

ID=21871750

Family Applications (2)

Application Number Title Priority Date Filing Date
DE198080301357T Pending DE18795T1 (de) 1979-04-26 1980-04-25 Einen monoklonalen antikoerper produzierende hybridzellinie, antikoerper und verfahren zu seiner herstellung, diesen antikoerper enthaltende therapeutische zusammensetzung und deren diagnostische und therapeutische verwendungen.
DE8080301357T Expired DE3070803D1 (en) 1979-04-26 1980-04-25 Monoclonal-antibody-producing hybrid cell line, antibody and method of preparing it, therapeutic composition containing it and its diagnostic and therapeutic uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE8080301357T Expired DE3070803D1 (en) 1979-04-26 1980-04-25 Monoclonal-antibody-producing hybrid cell line, antibody and method of preparing it, therapeutic composition containing it and its diagnostic and therapeutic uses

Country Status (22)

Country Link
US (1) US4361549A (enExample)
EP (1) EP0018795B2 (enExample)
JP (2) JPS55145617A (enExample)
AT (1) ATE14023T1 (enExample)
AU (1) AU544791B2 (enExample)
CA (1) CA1182406A (enExample)
DE (2) DE18795T1 (enExample)
DK (1) DK154769C (enExample)
ES (1) ES8105152A1 (enExample)
FI (1) FI75183C (enExample)
HK (1) HK23886A (enExample)
IE (1) IE50422B1 (enExample)
IL (1) IL59917A (enExample)
MY (1) MY8600514A (enExample)
NL (1) NL930131I2 (enExample)
NO (1) NO159221C (enExample)
NZ (1) NZ193469A (enExample)
PH (1) PH16642A (enExample)
PT (1) PT71147B (enExample)
SG (1) SG6686G (enExample)
YU (1) YU48442B (enExample)
ZA (1) ZA802525B (enExample)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582797A (en) * 1980-09-25 1986-04-15 The Salk Institute For Biological Studies Monoclonal antibodies specific for human hematopoietic cell surface glycoproteins
DE3105150A1 (de) * 1981-02-12 1982-08-19 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Herstellung von anti-t-lymphozyten-globulin.
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4657852A (en) * 1982-04-02 1987-04-14 The Board Of Trustees Of The Leland Stanford Junior University Method for B cell typing of total human lymphocyte sample
US4471056A (en) * 1982-04-02 1984-09-11 The Board Of Trustees Of The Leland Stanford Junior University Method for HLA-DR typing of total human lymphocyte sample
US4511662A (en) * 1982-06-18 1985-04-16 Bio-Rad Laboratories, Inc. Simultaneous assay for T and B lymphocyte populations and subpopulations
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
US4500637A (en) * 1982-07-19 1985-02-19 The United States Of America As Represented By The Department Of Health And Human Services Prevention of graft versus host disease following bone marrow transplantation
US4714613A (en) * 1982-09-30 1987-12-22 The Albert Einstein College Of Medicine Of Yeshiva University Method of suppressing cell growth by immunotherapy
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4797475A (en) * 1983-05-20 1989-01-10 The Regents Of The University Of California Method and composition for isolating white cell elements
US4645738A (en) * 1983-09-30 1987-02-24 Memorial Sloan-Kettering Institute Cancer Center Method for differential diagnosis of T cell leukemias using monoclonal antibodies
US4468346A (en) * 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
JPS60231699A (ja) * 1983-11-09 1985-11-18 Aichiken 正常及び悪性ヒト造血器細胞に対するモノクローナル抗体
US4672044A (en) * 1984-08-24 1987-06-09 Scripps Clinic & Research Foundation Murine monoclonal antibody combining site to human C3b receptor (CR1)
US4661446A (en) * 1985-02-19 1987-04-28 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies and method of immunizing therewith
US5431897A (en) * 1985-04-19 1995-07-11 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
US5091178A (en) * 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4970299A (en) * 1986-07-03 1990-11-13 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies selective for prostate cancer
US5158885A (en) * 1987-10-16 1992-10-27 Biomedical Systems Ltd Mouse monoclonal antibodies raised to the t-cell line hsb-2 and t-cell chronic lymphocytic leukemia (t-cll) cells react with normal human t and b lymphocytes and monocytes
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
JPH0291833U (enExample) * 1988-12-29 1990-07-20
JPH0277212U (enExample) * 1989-01-25 1990-06-13
EP0497883B1 (en) * 1989-10-27 1998-07-15 Arch Development Corporation Compositions and their use for promoting immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
JPH0420550U (enExample) * 1990-06-11 1992-02-20
US5444155A (en) * 1991-09-10 1995-08-22 The Scripps Research Institute Molecules with antibody combining sites that induce asymmetry
US5250426A (en) * 1991-10-22 1993-10-05 The Scripps Research Institute Molecules with antibody combining sites that induce asymmetry
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
FI960566L (fi) * 1993-09-03 1996-03-01 Chugai Pharmaceutical Co Ltd Monoklonaalinen vasta-aine, joka tunnistaa välisolun pinta-antigeenin
GB9513733D0 (en) * 1995-07-05 1995-09-06 Univ Bristol Therapeutic agents
EP2057999A3 (en) 1995-12-22 2009-07-29 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
PT963377E (pt) 1996-08-30 2009-05-11 Human Genome Sciences Inc Interleucina 19
CA2310805A1 (en) 1997-11-24 1999-06-03 Johnson T. Wong Methods for treatment of hiv or other infections using a t cell or viral activator and anti-retroviral combination therapy
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US8557868B2 (en) * 2000-11-04 2013-10-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions using low molecular weight amines
PT1331902E (pt) * 2000-11-08 2008-12-02 Fxs Ventures Llc Soluções oftálmicas e para lentes de contacto melhoradas contendo formas de vitamina b
US9308264B2 (en) 2000-11-08 2016-04-12 Fxs Ventures, Llc Ophthalmic contact lens solutions containing forms of vitamin B
US20070110782A1 (en) * 2000-11-08 2007-05-17 Fxs Ventures, Llc L-histidine in ophthalmic solutions
US20070104744A1 (en) * 2000-11-08 2007-05-10 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing forms of vitamin b
DK1339418T3 (da) * 2000-11-08 2009-12-14 Fxs Ventures Llc Forbedret ophthalmiske og kontaktlinseoplösninger indeholdende simple saccharider som konserverende forstærkere
US20060127496A1 (en) * 2000-11-08 2006-06-15 Bioconcept Laboratories L-histidine in ophthalmic solutions
US20060148665A1 (en) * 2000-11-08 2006-07-06 Bioconcept Laboratories Ophthalmic and contact lens solutions containing forms of vitamin b
US9492582B2 (en) * 2000-11-08 2016-11-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
RU2179862C1 (ru) * 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки
US7939501B2 (en) * 2003-04-15 2011-05-10 Smith Francis X Ophthalmic and contact lens solutions containing peptides as preservative
US8076459B2 (en) * 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
WO2005048935A2 (en) * 2003-11-14 2005-06-02 Brigham And Women's Hospital, Inc. Methods of modulating immunity
SG177944A1 (en) * 2005-07-11 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
AU2007260687B2 (en) * 2006-06-14 2013-12-12 Provention Bio, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
EP2094302A4 (en) * 2006-12-21 2010-12-08 Macrogenics Inc METHODS FOR THE TREATMENT OF LADA-LIKE DIABETES AND OTHER AUTOIMMUNE DIABETES OF THE ADULT USING IMMUNOSUPPRESSANT MONOCLONAL ANTIBODIES HAVING REDUCED TOXICITY
ES2581318T3 (es) 2009-07-17 2016-09-05 Bioatla Llc Selección y evolución simultáneas e integradas de rendimiento y expresión de anticuerpos/proteínas en huéspedes de producción
CA2804976A1 (en) 2010-04-29 2011-11-03 Hadasit Medical Research Services And Development Ltd. Methods and compositions for treating hepatitis with anti-cd3 immune molecule therapy
SG187033A1 (en) 2010-07-16 2013-02-28 Bioatla Llc Novel methods of protein evolution
JP2014500879A (ja) 2010-11-16 2014-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法
CN103620032B (zh) 2010-12-31 2016-02-24 生物蛋白有限公司 抗体的快速人源化
AU2011352207B2 (en) 2010-12-31 2016-03-03 Bioatla, Llc Comprehensive monoclonal antibody generation
RU2746407C1 (ru) 2012-02-23 2021-04-13 Стейдж Селл Терапеутикс Гмбх Хроматографическое выделение клеток и других сложных биологических материалов
KR102089526B1 (ko) 2012-05-10 2020-03-17 바이오아트라, 엘엘씨 다중-특이적 모노클로날 항체
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US11293929B2 (en) 2014-01-07 2022-04-05 Bioatla, Inc. Proteins targeting orthologs
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
IL293587B2 (en) 2014-04-16 2025-02-01 Juno Therapeutics Gmbh Methods, kits and devices for increasing cell populations
CN106459917B (zh) 2014-04-23 2021-03-09 朱诺治疗学股份有限公司 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
BR112017001579A2 (pt) 2014-07-25 2017-11-21 Cytomx Therapeutics Inc anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
SMT202000438T1 (it) 2014-11-17 2020-09-10 Regeneron Pharma Metodi per trattamento di tumore usando l'anticorpo bispecifico cd3xcd20
LT3247725T (lt) 2015-01-23 2020-10-12 Sanofi Anti-cd3 antikūnai, anti-cd123 antikūnai ir bispecifiniai antikūnai, specifiškai surišantys cd3 ir (arba) cd123
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
MA45426A (fr) 2015-10-22 2019-05-01 Juno Therapeutics Gmbh Procédés, kits, agents et appareils de transduction
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
CN115850521A (zh) 2016-02-05 2023-03-28 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
CN111032850B (zh) 2017-04-27 2024-08-13 朱诺治疗学有限公司 寡聚粒子试剂及其使用方法
EP3874024A1 (en) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Methods for selection and stimulation of cells and apparatus for same
WO2020097132A1 (en) 2018-11-06 2020-05-14 Juno Therapeutics, Inc. Process for producing genetically engineered t cells
US20220348660A1 (en) 2019-10-02 2022-11-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of adult t-cell leukemia/lymphoma
WO2021084050A1 (en) 2019-10-30 2021-05-06 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
KR20220152220A (ko) 2020-02-12 2022-11-15 주노 쎄러퓨티크스 인코퍼레이티드 Ｃｄ19-지시된 키메라 항원 수용체 ｔ 세포 조성물 및 이의 방법 및 용도
EP4103203A1 (en) 2020-02-12 2022-12-21 Juno Therapeutics, Inc. Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof
WO2021180821A2 (en) 2020-03-10 2021-09-16 Tiziana Life Sciences Plc Compositions of il-6/il-6r antibodies and methods of use thereof
US20230181641A1 (en) 2020-05-13 2023-06-15 Juno Therapeutics, Inc. Process for producing donor-batched cells expressing a recombinant receptor
US20230190804A1 (en) 2020-06-17 2023-06-22 Tiziana Life Sciences Plc Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies
IL299744A (en) 2020-07-30 2023-03-01 Tiziana Life Sciences Plc Antibodies to CD-3 for the treatment of the corona virus
EP4323404A1 (en) 2021-04-16 2024-02-21 Tiziana Life Sciences PLC Subcutaneous administration of antibodies for the treatment of disease
EP4334341A2 (en) 2021-05-06 2024-03-13 Juno Therapeutics GmbH Methods for stimulating and transducing t cells
US20240425591A1 (en) 2021-10-14 2024-12-26 Tiziana Life Sciences Plc Methods of suppressing microglial activation
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250101104A1 (en) 2022-01-26 2025-03-27 Mabswitch Inc. Bispecific molecule with tunable affinity to a targeted antigen
WO2023147510A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Chromatography arrays and related methods and kits
EP4472646A1 (en) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
EP4532695A1 (en) 2022-05-25 2025-04-09 Celgene Corporation Methods of manufacturing t cell therapies
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
CN121100267A (zh) 2022-12-09 2025-12-09 朱诺治疗学股份有限公司 使用全息成像预测细胞表型的机器学习方法
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法
CN121127253A (zh) 2023-02-28 2025-12-12 朱诺治疗学股份有限公司 治疗系统性自身免疫性疾病的细胞疗法
WO2024243340A1 (en) 2023-05-23 2024-11-28 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025049254A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. Pyrazolopyridine based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
WO2025049250A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. 6,6-core silacycle based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
WO2025049253A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. Bridged cycle‑based inhibitors of dna‑dependent protein kinase and compositions and application in gene editing
WO2025049247A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. 5,6-core silacycle based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
WO2025083196A1 (en) 2023-10-18 2025-04-24 Tq Therapeutics Gmbh A method of manufacturing a cellular therapy product and respective kits and devices
US20250241912A1 (en) 2024-01-25 2025-07-31 Juno Therapeutics, Inc. Use of bridged cycle-based inhibitors of dna-dependent protein kinase in combination of dna polymerase theta inhibitor and compositions and application in gene editing
WO2025179188A1 (en) 2024-02-22 2025-08-28 Juno Therapeutics, Inc. Pyrazole-based inhibitors of dna-dependent protein kinase and compositions and applications in gene editing
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR956062A (enExample) * 1950-01-24
GB824492A (en) * 1955-10-07 1959-12-02 Frederick William Beinlich Process and apparatus for the generation of power
US3988895A (en) * 1974-01-11 1976-11-02 Itzhak Sheinbaum Power generation from hot brines
US3986362A (en) * 1975-06-13 1976-10-19 Petru Baciu Geothermal power plant with intermediate superheating and simultaneous generation of thermal and electrical energy
US4089175A (en) * 1975-06-23 1978-05-16 Occidental Petroleum Corporation Process and system for recovery of energy from geothermal brines and other water containing sources by direct contact with a working fluid below the critical pressure
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
BE875277A (fr) * 1979-04-02 1979-10-02 Jourdain Leon J Machine motrice
US4284412A (en) * 1979-07-13 1981-08-18 Ortho Diagnostics, Inc. Method and apparatus for automated identification and enumeration of specified blood cell subclasses

Also Published As

Publication number Publication date
JPH0159868B2 (enExample) 1989-12-20
IL59917A (en) 1983-12-30
AU5775780A (en) 1980-10-30
NL930131I2 (nl) 1998-07-01
NZ193469A (en) 1984-07-06
EP0018795B1 (en) 1985-06-26
EP0018795B2 (en) 1999-04-07
DK154769B (da) 1988-12-19
NL930131I1 (nl) 1993-11-01
FI75183C (fi) 1988-05-09
EP0018795A3 (en) 1981-01-07
IE800840L (en) 1980-10-24
ES490944A0 (es) 1981-05-16
PT71147A (en) 1980-05-01
PT71147B (en) 1981-08-11
NO159221B (no) 1988-08-29
DK154769C (da) 1989-06-19
DK180380A (da) 1980-10-27
FI75183B (fi) 1988-01-29
IL59917A0 (en) 1980-06-30
EP0018795A2 (en) 1980-11-12
CA1182406A (en) 1985-02-12
IE50422B1 (en) 1986-04-16
ZA802525B (en) 1981-12-30
SG6686G (en) 1986-08-01
HK23886A (en) 1986-04-11
NO801214L (no) 1980-10-27
AU544791B2 (en) 1985-06-13
MY8600514A (en) 1986-12-31
JPS6362520B2 (enExample) 1988-12-02
YU114680A (en) 1984-02-29
DE3070803D1 (en) 1985-08-01
YU48442B (sh) 1998-07-10
ES8105152A1 (es) 1981-05-16
US4361549A (en) 1982-11-30
NO159221C (no) 1988-12-07
PH16642A (en) 1983-12-06
FI801342A7 (fi) 1980-10-27
ATE14023T1 (de) 1985-07-15
JPH0198478A (ja) 1989-04-17
JPS55145617A (en) 1980-11-13

Similar Documents

Publication Publication Date Title
DE18795T1 (de) Einen monoklonalen antikoerper produzierende hybridzellinie, antikoerper und verfahren zu seiner herstellung, diesen antikoerper enthaltende therapeutische zusammensetzung und deren diagnostische und therapeutische verwendungen.
DE18794T1 (de) Monoklonaler antikoerper gegen menschliche helfer-t-zellen, verfahren zu seiner herstellung, ihn produzierende hybridzellinie, seine diagnostischen und therapeutischen verwendungen und diesen antikoerper enthaltende diagnostische und therapeutische zusammensetzungen.
DE30815T1 (de) Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches prothymozyt-antigen
DE17381T1 (de) Monoklonaler antikoerper gegen menschliche t-zellen, verfahren zu seiner herstellung, ihn produzierende hybridzellinie, ihn enthaltende therapeutische zusammensetzung und ihn verwendendes diagnostisches verfahren.
DE3888172T2 (de) Rekombinant-antikörper.
DE3382764T2 (de) Humane-humane hybridomas für neoplasmen.
DE33578T1 (de) Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches t-zellen-antigen, antikoerper und verfahren.
DE69031410T2 (de) Monoklonale Antikörper gegen den humanen alpha/beta-T-Zellenrezeptor, ihre Herstellung und Verwendung
DE69330523T2 (de) Immunoglobuline ohne leichte ketten
DE30450T1 (de) Hybridzellinie zur herstellung komplementfixierender monoklonaler antikoerper gegen menschliche suppressor-t-zellen
DE69530975T2 (de) Rekombinante humanisierte antikörper gegen lewis y
DE69133200T2 (de) Spezifisch bindende Agentien
DE69319662T2 (de) Monoklonale Antikörper gegen GP130-Protein
DE33579T1 (de) Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches monozyt-antigen, antikoerper und verfahren.
DE25722T1 (de) Monoklonaler antikoerper gegen menschliche zytotoxische und suppressor-t-zellen und verfahren zu dessen herstellung.
DE69226990T2 (de) Tumorantigen-spezifischer Antikörper
EP0531300B1 (de) Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie
DE30814T1 (de) Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches fruehes thymozyt-antigen
AT400577B (de) Verfahren zur herstellung eines monoklonalen antikörpers und verfahren zum nachweisen von malignen zellen
DE30449T1 (de) Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches thymozyt-antigen, antikoerper und verfahren zu seiner herstellung, diagnostische und therapeutische verwendungen und diesen antikoerper enthaltende pharmazeutische zusammensetzungen.
DE3780480T2 (de) Test fuer menschlichen brustkrebs.
DE3853481T2 (de) Fv Antikörperfragment-Herstellung.
DE57107T1 (de) Verfahren zur herstellung von monoklonalen antikoerpern und zellen, faehig diese antikoerper herzustellen.
DE3490527C2 (enExample)
DE69115938T2 (de) Monoklonaler Antikörper zur Erkennung eines Anthracyclinglycosid-spezifischen Epitopes und diesen Antikörper herstellendes Hybridoma